Key Figures Q3 2021

SEK m, unless otherwise stated

2021

Jul-Sep

2020

Jul-Sep

2021

Jan-Sep

2020

Jan-Sep

2020

Jan-Dec

Net revenues

145.9

150.3

421.0

504.4

663.6

Cost of goods sold

-21.3

-14.5

-58.6

-54.3

-65.6

Operating expenses

-183.7

-165.4

-512.4

-459.0

-617.9

EBIT

-59.0

-29.6

-150.0

-8.9

-19.9

EBIT margin, %

-40.5

-19.7

-35.6

-1.8

-3.0

EBITDA

-47.4

-20.9

-112.6

17.9

19.0

Earnings per share, before dilution, SEK

-1.51

-2.45

-4.59

-1.00

-2.45

Earnings per share, after dilution, SEK

-1.51

-2.45

-4.59

-1.00

-2.45

Cash flow from operating activities

-79.7

-12.9

-148.4

28.0

16.8

Cash and cash equivalents

588.1

593.3

588.1

593.3

505.3

Net revenues and EBIT per segment Q3 2021

SEK m

Net Revenues

EBIT

 

2021  Jul-Sep

2020  Jul-Sep

2021 Jan-Sep

2020 Jan-Sep

2020 Jan-Dec

2021  Jul-Sep

2020  Jul-Sep

2021 Jan-Sep

2020 Jan-Jun

2020 Jan-Dec

ZUBSOLV® US

136.4

143.8

389.2

480.2

623.3

-

-

-

-

-

US Pharma – total

136.4

143.8

389.2

480.2

623.3

78.5

72.4

206.1

237.2

331.2

Digital Therapeutics (DTx) product sales

0.4

-

0.8

-

0.0

-

-

-

-

-

Digital Therapeutics (DTx) – total

0.4

-

0.8

-

0.0

-76.4

-62.5

-186.7

-110.1

-175.4

Abstral® royalties

6.8

2.5

23.8

14.6

29.7

-

-

-

-

-

Edluar® royalties

2.4

4.0

7.2

9.5

10.4

-

-

-

-

-

ZUBSOLV® - ex US

-

-

-

0.1

0.1

-

-

-

-

-

HQ & Pipeline segment - total

9.2

6.5

31.0

24.2

40.2

-61.2

-39.5

-169.3

-136.0

-175.8

Total

145.9

150.3

421.0

504.4

663.6

-59.1

-29.6

-150.0

-8.9

-19.9


Cash flow Q3 2021

 

SEK m

2021

Jul-Sep

2020

Jul-Sep

2021

Jan-Sep

2020

Jan-Sep

2020

Jan-Dec

Cash flow from operating activities

-79.7

-12.9

-148.4

28.0

16.8

Investment activities

-20.7

-50.2

-50.0

-160.1

-189.2

Financing activities

-2.0

-4.2

256.1

-106.9

-111.3

Cash flow (excl exchange rate differences)

-102.4

-67.4

57.7

-239.1

-283.7

Liquid funds

588.1

593.3

588.1

593.3

505.3